Maegan Hoover, MS

Maegan is a Scientist II in the Discovery group at GentiBio. Maegan most recently came from Rubius Therapeutics, where she played an integral role in the preclinical development of several broadly stimulating anti-cancer cellular therapies. At Rubius, Maegan was fortunate to see two oncology candidates from initial proof of concept studies through to IND approval; one of which is currently in phase 1/2 clinical trials. Maegan began her industry career at Genocea Biosciences where she worked on T cell focused vaccine development, assisting in mouse model development and early-stage immunogenicity and efficacy experiments for both the Chlamydia vaccine program, and later a neoantigen targeted personalized cancer vaccine program. Prior to industry work, Maegan spent several years in academia, working on a range of research topics, from the molecular drivers of RETT syndrome, long term metabolic impacts of perinatal bisphenol A exposure, and pro-drug design for the treatment of cancer and type 1 diabetes. Maegan earned her B.A. in Biology from Connecticut College and received her Master of Science in the Biological Sciences, with a focus on molecular biotechnology, from Tufts University. When not working, Maegan enjoys crossfitting, creating tiktoks of her dog, eating oatmeal chocolate chip cookies (no raisins allowed), and backpacking above 66° north of the equator.